ArticleScientific reports2026
Integrative machine learning and molecular docking reveal Narirutin targets ABCC1/ABCG2 for immune microenvironment remodeling in colorectal cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide, with late-stage diagnosis often associated with poor prognosis. The natural compound narirutin has shown various biological activities, including anti-inflammatory and anti-cancer effects, indicating its potential clinical application. This study aims to identify the key targets and potential mechanisms of narirutin treatment in colorectal cancer (CRC) through comprehensive bioinformatics analysis and machine learning methods, emphasizing its importance as a potential therapeutic agent. We utilized SwissTargetPrediction to identify 23 target genes of narirutin, followed by differential expression analysis of 3,338 genes from the TCGA-COAD dataset. We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses on the intersecting genes, and machine learning techniques to identify hub genes. Additionally, we conducted molecular docking studies and immune infiltration analyses. Our findings revealed that narirutin targets key genes, including ABCC1, ABCG2, CA12, EPHX2, and PTGS1, which are significantly involved in CRC progression. Enrichment analyses indicated that these genes participate in crucial pathways related to drug metabolism and immune response. Molecular docking results demonstrated favorable binding affinities between narirutin and its target proteins. Furthermore, immune cell infiltration analysis showed significant differences in various immune cell types between CRC and control groups, suggesting their role in tumor microenvironment dynamics. Narirutin may play a vital role in CRC treatment by modulating key genes and pathways, underscoring its potential as a therapeutic agent. Future studies should explore its clinical applicability and mechanisms further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.